PubMed=3472651
Kees U.R.
Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line.
Cancer Res. 47:3088-3091(1987)

PubMed=2720661
Kees U.R., Ford J., Dawson V.M., Piall E.M., Aherne G.W.
Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Cancer Res. 49:3015-3019(1989)

PubMed=7540895; DOI=10.1097/00001813-199504000-00015
Kees U.R., Avramis V.I.
Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163.
Anticancer Drugs 6:303-310(1995)

PubMed=7541097
Kees U.R., Ashman L.K.
Synergistic action of interleukin-2 and Steel factor (SLF) on a human T lymphoblastoid cell line.
Leukemia 9:1046-1050(1995)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=12883040
Kees U.R., Ford J., Watson M., Murch A.R., Ringner M., Walker R.L., Meltzer P.S.
Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease.
Mol. Cancer Ther. 2:671-677(2003)

PubMed=17117183; DOI=10.1038/sj.bjc.6603447; PMCID=PMC2360743
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)